CJC-1295 NO DAC + Ipamorelin Blend

CJC-1295 NO DAC + Ipamorelin is a 1:1 dual-peptide blend containing CJC-1295 (without Drug Affinity Complex) and Ipamorelin, designed for growth hormone optimization.

Profile · 01

Overview

CJC-1295 NO DAC + Ipamorelin is a 1:1 dual-peptide blend containing CJC-1295 (without Drug Affinity Complex) and Ipamorelin, designed for growth hormone optimization. CJC-1295 (no DAC) stimulates pulsatile GH release from the pituitary with a shorter duration than the DAC variant; Ipamorelin is a pentapeptide ghrelin mimetic that selectively stimulates GH release without affecting ACTH, cortisol, or prolactin levels. Neither peptide is FDA-approved for the indications described.

Evidence is drawn from clinical pharmacokinetic studies and preclinical models. This protocol presents a once-daily subcutaneous titration approach using practical dilution for clear insulin-syringe measurements.

At a Glance

Goal
Support growth hormone optimization, recovery, sleep quality, and anti-aging
Categories
GH OptimizationRecoveryAnti-AgingSleep Support
Synergistic
GHRP-2 · GHRP-6 · Sermorelin · MK-677 · BPC-157
Profile · 02

Protocol

Suggested daily titration approach starting low and increasing every two weeks.

Typical daily range
200–600 mcg total once daily (100–300 mcg each peptide; gradual titration)
Start
200 mcg total daily (100 mcg each); increase by ~50–100 mcg per peptide every 2 weeks
Target
500–600 mcg total daily (250–300 mcg each) by Weeks 7–12
Frequency
Once per day (subcutaneous), typically before bed or upon waking
Cycle Length
8–12 weeks; optional extension to 16 weeks
Timing
Before bed or upon waking; rotate injection sites
Route
Subcutaneous
Cycle
8–12 weeks on, 4 weeks off

Inject once daily subcutaneously using the largest practical dilution to maintain measurement accuracy. The combination targets both GHRH and ghrelin pathways for sustained, selective GH elevation. CJC-1295 (no DAC) provides pulsatile GH stimulation, while Ipamorelin adds selective GH release without cortisol elevation. Dosing is based on clinical pharmacokinetic data; large-scale human efficacy data for the combination remain limited.

Dose progression

Weeks 1–2
100 mcg each (200 mcg total)
Weeks 3–4
150 mcg each (300 mcg total)
Weeks 5–6
200 mcg each (400 mcg total)
Weeks 7–12
250–300 mcg each (500–600 mcg total)

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Profile · 03

Videos

Science · 01

How CJC-1295 NO DAC + Ipamorelin Blend works.

CJC-1295 (without Drug Affinity Complex) is a synthetic GHRH analog that stimulates pulsatile GH release from the pituitary. Without the DAC modification, it has a shorter half-life than CJC-1295 with DAC, producing more physiologic GH pulsing patterns. Ipamorelin is a pentapeptide ghrelin mimetic that demonstrates selective GH release without affecting ACTH, cortisol, or prolactin levels — making it one of the cleanest GH secretagogues available. Combined, the two peptides provide sustained GH and IGF-1 elevation through complementary pulsatile patterns. Clinical studies confirm selectivity of both components, but large-scale controlled human efficacy data on the combined blend remain unavailable.

Science · 02

Effects

Observations from clinical or preclinical literature.

Sustained GH and IGF-1 elevation through complementary pulsatile patterns
Ipamorelin demonstrates selective GH release without cortisol, ACTH, or prolactin elevation
General tolerability with a favorable side-effect profile compared to other GH secretagogues
Possible transient effects including flushing, headache, or injection-site reactions
Increased appetite, water retention, or tingling sensations may occur
Long-term human safety and efficacy of the combination remain under investigation
Science · 03

Caution

Individuals with active cancer or a history of cancer should avoid use due to GH-stimulating properties
Not recommended during pregnancy or breastfeeding (no safety data available)
Use with caution in individuals with diabetes or insulin resistance, as GH-releasing peptides may affect glucose metabolism
Consult a healthcare provider before use if you have any chronic medical conditions or are on medications

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Lifestyle · 01

CoFactors

Zinc
Supports GH signaling and immune function.
Magnesium
Supports enzymatic processes involved in GH release and sleep quality.
Vitamin D
Supports metabolic health and hormonal balance.
B Vitamins
Support energy metabolism and neurotransmitter function.
Lifestyle · 02

Life Factors

Complementary strategies for best outcomes.

Maintain a protein-forward diet to support lean mass and recovery goals
Combine resistance training with regular aerobic activity for optimal body composition
Prioritize sleep (7–9 hours) — GH release is closely linked to sleep architecture
Manage stress and maintain consistent daily routines for hormonal optimization
Lifestyle · 03

Metrics

Day-to-day metrics worth tracking through the protocol.

  1. Body composition (weight, body fat percentage, lean mass) — monitor changes to gauge anabolic response
  2. Sleep quality and duration — GH release is closely tied to deep sleep stages
  3. Energy levels, mood, and recovery — subjective markers of GH-axis improvement
  4. Injection-site reactions — note any redness, swelling, or flushing to guide site rotation
Lifestyle · 04

Labs

Baseline and periodic bloodwork to monitor systemic health during the protocol.

IGF-1
Primary marker of GH axis activity; monitor before and during protocol.
Fasting Glucose / HbA1c
Monitor metabolic impact of GH-releasing peptides.
CBC (Complete Blood Count)
Monitor overall health and rule out underlying conditions.
CMP (Comprehensive Metabolic Panel)
Assess liver and kidney function during peptide use.
Calculators · 01

Supplies Calculator

Estimates assume the schedule defined for this peptide.

Length
Vial size
Bac. water
Syringe
Vials
0 × 10 mg each…
Syringes
0
Bac. water
0 mL
Swabs
02 per syringe
Calculators · 02

Dose Calculator

Dose Calculator

Vial
Bac. water
Syringe
Dose
Concentration
0mcg/mL
Volume per dose
0mL
…
Practice · 01

Preparation

Careful technique preserves potency. Solution should be clear — do not shake.

  1. Allow vial to reach room temperature for 15–20 minutes before reconstitution.
  2. Draw the chosen bacteriostatic water volume with a sterile syringe.
  3. Inject slowly down vial wall; avoid foaming.
  4. Gently swirl/roll until dissolved (do not shake).
  5. Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
  6. Use within 30 days; discard any unused solution after 30 days.
Practice · 02

Technique

General subcutaneous guidance from clinical best-practice resources.

Clean vial stopper and skin with alcohol; allow to dry
Pinch a skinfold; insert needle at 45–90° into subcutaneous tissue
Do not aspirate for subcutaneous injections; inject slowly and steadily
Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy
Discard used syringes immediately in sharps container per WHO guidelines

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Practice · 03

Storage

Lyophilized
Store at room temp in dry, dark conditions; minimize moisture exposure.
Reconstituted
Refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles. Discard reconstituted vials after 30 days.

Notes

Allow vials to reach room temperature before opening to reduce condensation uptake.
Reference · 01

Notes

Use new sterile insulin syringes for each injection; dispose in sharps container
Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation
Inject slowly; wait a few seconds before withdrawing the needle
Document daily dose and site rotation to maintain consistency
Administer before bed or upon waking for optimal GH pulsing alignment
Human data on this specific combination are limited; clinical decisions should involve qualified healthcare providers
Reference · 02

References

  1. Journal of Clinical Endocrinology & Metabolism
    Teichman SL et al., "Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295".
    https://pubmed.ncbi.nlm.nih.gov/16352683/
  2. Regulatory Peptides
    Raun K et al., "Ipamorelin, the first selective growth hormone secretagogue".
    https://pubmed.ncbi.nlm.nih.gov/9700053/
  3. Growth Hormone & IGF Research
    Johansen PB et al., "Ipamorelin: a new growth-hormone-releasing peptide".
    https://pubmed.ncbi.nlm.nih.gov/10352355/
  4. European Journal of Endocrinology
    Ionescu M et al., "Pulsatile growth hormone secretion in humans: physiological and clinical implications".
    https://pubmed.ncbi.nlm.nih.gov/10724528/
  5. WHO (NCBI Bookshelf)
    "Guideline on safety-engineered syringes for IM, ID, and SC injections in health care settings (2016)".
    https://www.ncbi.nlm.nih.gov/books/NBK390474/
  6. Johns Hopkins Arthritis Center
    "How to give a subcutaneous injection (patient education resource)".
    https://www.hopkinsarthritis.org/patient-corner/how-to-give-a-subcutaneous-injection/
  7. CDC
    "Vaccine administration: subcutaneous route (angle/site; no aspiration)".
    https://www.cdc.gov/vaccines/hcp/admin/downloads/YCTS-VaxAdmin-Subcut-injection.pdf
  8. Subcutaneous Drug Injection Review (PMC)
    "Pharmacologic considerations of the subcutaneous route".
    https://pmc.ncbi.nlm.nih.gov/articles/PMC6822791/
On this page